Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.12% | -61.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.81% | -32.68% | |||
| Operating Income | 14.81% | 32.68% | |||
| Income Before Tax | 14.74% | 32.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 14.74% | 32.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.74% | 32.92% | |||
| EBIT | 14.81% | 32.68% | |||
| EBITDA | 14.83% | 32.71% | |||
| EPS Basic | 74.29% | 33.01% | |||
| Normalized Basic EPS | 74.29% | 33.01% | |||
| EPS Diluted | 74.29% | 33.01% | |||
| Normalized Diluted EPS | 74.29% | 33.01% | |||
| Average Basic Shares Outstanding | 231.64% | 0.13% | |||
| Average Diluted Shares Outstanding | 231.64% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||